AMGNAmgen
Is it growing?
Growing: earnings up +32% year on year and operating margin widening (+6.7 points).
Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +8% a year.
Trailing-twelve-month earnings per share against a year earlier. Growing faster than revenue, so margins or the share count are helping.
Trailing-twelve-month operating margin, 30.0% now against 23.2% a year earlier.
All from SEC EDGAR, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.
Is AMGN growing?
Amgen has grown revenue 13% a year over three years and 8.4% a year over five, with earnings per share compounding at 2.8%.
Revenue growth, 3-year annual rate · Drug Manufacturers - General median +6.3% · steady growth, ahead of inflation · compounded from trailing twelve-month revenue
- Revenue growth, 5-year rate
- +8.4%
Revenue growth, 5-year rate · +13% over three · growth has picked up over the last three years
- Earnings per share, 3-year rate
- +2.8%
Earnings per share, 3-year rate · revenue +13% · earnings lagged revenue: the growth is costing something
- Years of annual history on file
- 19
Years of annual history on file · FY2007 to FY2025, as filed
Details›
- Revenue FY2021
- $26.0B
- Revenue FY2022
- $26.3B
- Revenue FY2023
- $28.2B
- Revenue FY2024
- $33.4B
- Revenue FY2025
- $36.8B
Annual income statements as filed with the SEC.
Drug Manufacturers, General
The closest names by size in the same industry